Roche’s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy

详细摘要
Approval based on phase III MAJESTY results demonstrating Gazyva/Gazyvaro superiority over tacrolimus in achieving complete remission of proteinuria at two years (36.1% vs. 5.7%; p
Basel, 16 November 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with primary membranous nephropathy (pMN) at risk of disease progression, to induce remission of proteinuria. Gazyva/Gazyvaro becomes the first and only therapy to receive FDA approval for this disease, having previously been granted Breakthrough Therapy Designation.
"The FDA approval of Gazyva/Gazyvaro represents an important step forward for people living with primary membranous nephropathy, where targeting B cells addresses a critical underlying driver of disease," said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. "With Gazyva/Gazyvaro, we are turning decades of specialised antibody engineering into tangible outcomes for patients with immune-mediated kidney diseases. By achieving significantly higher complete remission rates compared to tacrolimus, Gazyva/Gazyvaro offers a more effective approach to help achieve durabledisease control."
The approval is based on positive results from the phase III MAJESTY study.3 The trial met its primary endpoint, with 36.1% of adults achieving complete remission (CR) of proteinuria at two years (104 weeks) with Gazyva/Gazyvaro versus 5.7% with tacrolimus (adjusted difference 31.1%; 95% confidence interval [CI]: 18.2 to 44.0; p
"People living with primary membranous nephropathy face the risk of progressive kidney damage and significant uncertainty about their health," said Marc Hurlbert, PhD, Chief Executive Officer of the National Kidney Foundation. "The first FDA approval of a treatment specifically for this condition is a milestone, finally giving patients and clinicians more treatment options. Our hope is that the approval of Gazyva/Gazyvaro provides a turning point for people navigating pMN."
pMN is a rare, chronic autoimmune condition that causes potentially irreversible…
文章开头,摘自Yahoo Finance。如需阅读全文,请前往媒体网站。
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (finance.yahoo.com)




